MX343784B - Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos. - Google Patents

Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.

Info

Publication number
MX343784B
MX343784B MX2013003715A MX2013003715A MX343784B MX 343784 B MX343784 B MX 343784B MX 2013003715 A MX2013003715 A MX 2013003715A MX 2013003715 A MX2013003715 A MX 2013003715A MX 343784 B MX343784 B MX 343784B
Authority
MX
Mexico
Prior art keywords
factor
treatment
fibrinogen
clotting factor
haemostatic disorders
Prior art date
Application number
MX2013003715A
Other languages
English (en)
Spanish (es)
Other versions
MX2013003715A (es
Inventor
Lovgren Ann
Hansson Kenny
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343784(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2013003715A publication Critical patent/MX2013003715A/es
Publication of MX343784B publication Critical patent/MX343784B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2013003715A 2010-10-06 2011-09-19 Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos. MX343784B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06
PCT/EP2011/066241 WO2012045569A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Publications (2)

Publication Number Publication Date
MX2013003715A MX2013003715A (es) 2013-09-26
MX343784B true MX343784B (es) 2016-11-23

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003715A MX343784B (es) 2010-10-06 2011-09-19 Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.

Country Status (16)

Country Link
US (1) US9433664B2 (enExample)
EP (1) EP2624859B1 (enExample)
JP (1) JP6000259B2 (enExample)
KR (1) KR20130136988A (enExample)
CN (1) CN103221061A (enExample)
AU (1) AU2011313505B2 (enExample)
BR (1) BR112013008034A2 (enExample)
CA (1) CA2812888A1 (enExample)
DK (1) DK2624859T3 (enExample)
ES (1) ES2625153T3 (enExample)
HU (1) HUE033204T2 (enExample)
MX (1) MX343784B (enExample)
PL (1) PL2624859T3 (enExample)
RU (1) RU2606155C2 (enExample)
SG (2) SG10201508159SA (enExample)
WO (1) WO2012045569A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171463B2 (en) 2008-10-03 2024-12-24 Femasys Inc. Contrast agent generation and injection system for sonographic imaging
SG10201508159SA (en) 2010-10-06 2015-10-29 Medimmune Ltd Factor II And Fibrinogen For Treatment Of Haemostatic Disorders
IL230150A0 (en) * 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
JP7227905B2 (ja) 2017-02-09 2023-02-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血の処置または予防における使用のための血液凝固因子代替製品
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3165600D1 (en) 1980-01-28 1984-09-27 Baxter Travenol Lab Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
HUP9700603A3 (en) 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
ATE386538T1 (de) 2001-02-05 2008-03-15 Novo Nordisk Healthcare Ag Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
AU2002354846B2 (en) 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
EP1587424A4 (en) 2002-12-31 2012-01-25 Marinepolymer Tech Inc Bleeding Compounds and their uses
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1748781B1 (en) 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
EP1893230A2 (en) 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CA2644926A1 (en) * 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin and fibrinogen
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
WO2008051513A2 (en) 2006-10-23 2008-05-02 Allan Pronovost Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
US20080267940A1 (en) 2007-03-30 2008-10-30 Mohammed Syed F Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
NZ579985A (en) 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
EP2337793A4 (en) 2008-10-08 2013-04-10 Thrombodyne Inc METHOD FOR PRODUCING CONCENTRATED FIBRINOGEN AND PLAIN-CONTAINING COMPOSITIONS
SG10201508159SA (en) 2010-10-06 2015-10-29 Medimmune Ltd Factor II And Fibrinogen For Treatment Of Haemostatic Disorders

Also Published As

Publication number Publication date
AU2011313505A1 (en) 2013-04-11
DK2624859T3 (en) 2017-06-06
SG10201508159SA (en) 2015-10-29
WO2012045569A1 (en) 2012-04-12
CN103221061A (zh) 2013-07-24
AU2011313505B2 (en) 2015-09-17
US9433664B2 (en) 2016-09-06
MX2013003715A (es) 2013-09-26
JP2013538863A (ja) 2013-10-17
WO2012045569A9 (en) 2016-01-07
JP6000259B2 (ja) 2016-09-28
HUE033204T2 (en) 2017-11-28
EP2624859B1 (en) 2017-03-01
RU2013120033A (ru) 2014-11-20
ES2625153T3 (es) 2017-07-18
US20130280236A1 (en) 2013-10-24
EP2624859A1 (en) 2013-08-14
SG188639A1 (en) 2013-05-31
KR20130136988A (ko) 2013-12-13
CA2812888A1 (en) 2012-04-12
RU2606155C2 (ru) 2017-01-10
PL2624859T3 (pl) 2017-09-29
BR112013008034A2 (pt) 2016-06-14

Similar Documents

Publication Publication Date Title
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
MX343784B (es) Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
MX2010003095A (es) Antidotos para inhibidores del factor xa y metodos para usar los mismos.
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ611108A (en) Methods of treating fgf21-associated disorders
PH12013502149A1 (en) Modified acid alpha glucosidase with accelerated processing
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
WO2008103345A3 (en) Hemostatic compositions and therapeutic regimens
IN2014KN02830A (enExample)
NZ612533A (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
IN2012DN06309A (enExample)
MX363507B (es) Metodos para administrar óxido nítrico a la sangre arterial o arterializada.
GB2492738A (en) Conjugated blood coagulation factor VIIA
HK1213767A1 (zh) 使用固定劑量凝血因子的方法
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
NZ602380A (en) Peptides for vaccine against birch allergy
MX2013008530A (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX347805B (es) Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.
MX2016004702A (es) Polipeptidos del factor vii de coagulacion.
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
PH12018502133A1 (en) Conjugated c1 esterase inhibitor and uses thereof
BR112013009660A8 (pt) Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante

Legal Events

Date Code Title Description
FG Grant or registration